This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
Journal of pediatric hematology/oncology · 2009
Latest funding
- $2,250,000
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
CIHR · 2018 · Co-investigator
- $344,025
Development of child-friendly oral formulations for drugs used in the maintenance therapy of childhood acute lymphoblastic leukemia
CIHR · 2016 · Principal investigator
- $573,750
Discovery, validation, and pre-clinical development of novel strategies to prevent anthracycline-induced cardiotoxicity.
CIHR · 2016 · Co-investigator
1 publications.
In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
Paulus S, Dobson S, Rassekh S, Blondel-Hill E
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
Principal investigators: Carleton, Bruce C; Ross, Colin J
Keywords: Active Surveillance; Adr Reporting; Adverse Drug Reactions (Adrs); Drug Effectiveness; Drug Safety; Pharmacogenomics; Pharmacovigilance
Development of child-friendly oral formulations for drugs used in the maintenance therapy of childhood acute lymphoblastic leukemia
Principal investigators: Li, Shyh-Dar; Rassekh, Shahrad R
Keywords: Anticancer Drug Delivery; Lipid Nanoparticles; Oral Pediatric Formulation; Oro-Dispersible Formulation
Discovery, validation, and pre-clinical development of novel strategies to prevent anthracycline-induced cardiotoxicity.
Principal investigators: Ross, Colin J
Keywords: Adverse Drug Reaction; Anthracyclines; Cell Culture; Chemotherapy; Drug Development; Drug Effectiveness; Drug Safety; Genomics; Personalized Medicine; Preclinical
Active Surveillance for evaluation of harm of direct acting oral anticoagulants (DOACs) in real-world patients
Principal investigators: Carleton, Bruce C; Ross, Colin J
Keywords: Active Surveillance
DSEN active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare (DSEN SEARCH)
Principal investigators: Carleton, Bruce C
Keywords: Active Surveillance; Adverse Drug Reactions; Drug Safety; Post-Market Safety Evaluation
5-HT3 Antagonists (Antiemetics) & Cardiac Safety, Using an Active Surveillance Approach
Principal investigators: Carleton, Bruce C
Keywords: 5-Ht3 Antagonists; Active Surveillance; Adverse Drug Reactions; Antiemetics; Cardiac Safety; Qt Prolongation
Identification of pharmacogenomic variants for the prevention of vincristine-induced neurotoxicity.
Principal investigators: Ross, Colin J
Keywords: Adverse Drug Reaction; Chemotherapy; Genetics; Oncology; Pharmacogenomics; Vincristine
DSEN active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare (DSEN SEARCH)
Principal investigators: Carleton, Bruce C; Hayden, Michael R
Keywords: Active Surveillance; Adverse Drug Reactions; Drug Safety; Post-Market Safety Evaluation
Pharmacogenetics of Warfarin Safety and Effectiveness in Children.
Principal investigators: Ross, Colin J; Carleton, Bruce C
Keywords: Adverse Drug Reaction; Drug Effectiveness; Drug Safety; Pediatrics; Pharmacogenetics; Warfarin
Development of clinical practice guidelines for pharmacogenetic testing
Principal investigators: Carleton, Bruce C; Hayden, Michael R
Keywords: Clinical Practice Guidelines; Pharmacogenetic Testing
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.